EDGEWISE THERAPEUTICS INC's ticker is EWTX and the CUSIP is 28036F105. A total of 95 filers reported holding EDGEWISE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $7,593,088 | +2.8% | 421,604 | +4.1% | 0.07% | +5.9% |
| Q1 2024 | $7,389,608 | +67.1% | 405,132 | +0.2% | 0.07% | +41.7% |
| Q4 2023 | $4,422,079 | +114.3% | 404,212 | +12.3% | 0.05% | +100.0% |
| Q3 2023 | $2,063,333 | -26.1% | 360,093 | 0.0% | 0.02% | -27.3% |
| Q2 2023 | $2,790,721 | +16.2% | 360,093 | 0.0% | 0.03% | 0.0% |
| Q1 2023 | $2,401,820 | -25.4% | 360,093 | +0.0% | 0.03% | -23.3% |
| Q4 2022 | $3,219,214 | -39.4% | 360,091 | -33.3% | 0.04% | -41.9% |
| Q3 2022 | $5,312,000 | -13.5% | 539,864 | -30.1% | 0.07% | -22.1% |
| Q2 2022 | $6,144,000 | +75.9% | 771,797 | +114.3% | 0.10% | +66.7% |
| Q1 2022 | $3,493,000 | -43.3% | 360,093 | -10.6% | 0.06% | -35.2% |
| Q4 2021 | $6,156,000 | +2.5% | 402,849 | +11.3% | 0.09% | -10.2% |
| Q3 2021 | $6,006,000 | -20.6% | 361,821 | +2.1% | 0.10% | -30.5% |
| Q2 2021 | $7,561,000 | -34.9% | 354,489 | -0.8% | 0.14% | -45.3% |
| Q1 2021 | $11,616,000 | – | 357,429 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,553,661 | $27,981,435 | 34.02% |
| Novo Holdings A/S | 6,344,430 | $114,263,184 | 6.63% |
| Orbimed Advisors | 15,021,721 | $270,541,195 | 5.34% |
| TCG Crossover Management, LLC | 2,272,728 | $40,931,831 | 4.27% |
| Frazier Life Sciences Management, L.P. | 3,731,067 | $67,196,517 | 3.14% |
| Cormorant Asset Management, LP | 3,006,534 | $54,147,677 | 3.13% |
| Opaleye Management Inc. | 580,000 | $10,445,800 | 2.39% |
| RA Capital Management | 8,909,091 | $160,452,729 | 2.12% |
| VR Adviser, LLC | 1,818,182 | $32,745,458 | 2.08% |
| MPM BioImpact LLC | 740,661 | $13,339,305 | 2.07% |